Research shows that azacitidine and decitabine, two medications used to treat blood cancers, frequently cause serious stomach problems and nutrition issues in patients. According to Gram Research analysis of over 17,800 patient reports, a severe colon condition called neutropenic colitis was 23-26 times more likely to occur in patients taking these drugs, and tumor lysis syndrome was reported in 212 cases combined. Early monitoring of stomach symptoms, appetite, and blood chemistry can help doctors catch these problems quickly and provide better supportive care.
Researchers analyzed thousands of reports about two cancer medications called azacitidine and decitabine, which treat blood cancers. They found these drugs commonly cause stomach problems, appetite loss, and metabolism issues that can affect how well patients eat and recover. By studying real-world patient reports from a government database, scientists identified the most common side effects and when they typically happen. This information helps doctors better prepare patients and watch for warning signs during treatment.
Key Statistics
A 2026 pharmacovigilance analysis of 17,807 FDA reports found that neutropenic colitis was 23-26 times more likely to be reported in patients taking azacitidine or decitabine compared to other medications.
According to a 2026 analysis of over 17,800 patient safety reports, tumor lysis syndrome was reported in 165 patients taking azacitidine and 47 patients taking decitabine for blood cancer treatment.
A 2026 review of FDA safety data identified six major nutrition and metabolism problems associated with hypomethylating agents: electrolyte imbalances, low blood protein, iron overload, appetite loss, severe weight loss, and failure to thrive.
Research analyzing 17,807 reports from a U.S. safety database found that most gastrointestinal and metabolism side effects from azacitidine and decitabine were reported early in treatment, suggesting the first weeks and months require close medical monitoring.
The Quick Take
- What they studied: Which stomach and nutrition problems happen most often in patients taking azacitidine or decitabine for blood cancers, and when these problems usually start.
- Who participated: Over 17,800 patient reports from a U.S. government safety database tracking side effects from two cancer medications used to treat myelodysplastic syndromes and acute myeloid leukemia.
- Key finding: A serious stomach condition called neutropenic colitis was 23-26 times more likely to be reported in patients taking these drugs compared to other medications. Tumor lysis syndrome (a dangerous metabolic condition) was also frequently reported, with 165 cases linked to azacitidine and 47 to decitabine.
- What it means for you: If you or a loved one takes these cancer drugs, doctors should closely monitor stomach symptoms, appetite changes, and blood chemistry. Early detection of these side effects allows for faster treatment and better outcomes. This doesn’t mean avoiding the medication—it means being prepared and informed.
The Research Details
Researchers examined over 17,800 safety reports submitted to the FDA’s database (called FAERS) about two cancer medications: azacitidine and decitabine. These reports came from patients, doctors, and pharmacists who noticed side effects. The team used four different statistical methods to identify which stomach and nutrition problems were reported more often than expected, similar to how a detective looks for patterns in crime data.
They also checked a Canadian safety database to confirm their findings were real and not just a quirk of the U.S. data. For reports that included timing information, they used mathematical modeling to figure out when side effects typically appeared after patients started treatment. Finally, they conducted a computer analysis to explore how these drugs might cause these problems at the biological level.
This approach is important because it captures what actually happens to patients in real life, not just what happens in controlled research studies. Doctors and patients need to know the full range of side effects that can occur, including rare but serious ones. By identifying patterns early, doctors can monitor high-risk patients more carefully and catch problems before they become dangerous.
This study has several strengths: it analyzed a very large number of reports (over 17,800), used multiple statistical methods to confirm findings, and checked results in a second database from another country. However, the study relies on voluntary reports, so some side effects might be underreported or overreported. The data doesn’t prove the drug caused the problem—only that the problem was reported more often than usual. Patients taking these drugs may have other health conditions that could also cause these symptoms.
What the Results Show
The most serious stomach problem identified was neutropenic colitis (severe inflammation of the colon), which was 23-26 times more likely to be reported in patients taking these drugs. This is a medical emergency requiring immediate attention. The second major finding involved tumor lysis syndrome, a dangerous condition where cancer cells break down too quickly and release harmful substances into the bloodstream. This was reported in 165 patients taking azacitidine and 47 taking decitabine.
Other common problems included low blood protein levels (hypoalbuminemia), electrolyte imbalances (salt and mineral problems in the blood), severe weight loss and muscle wasting (cachexia), decreased appetite, and iron buildup in the body. These nutrition and metabolism problems can make it harder for patients to recover from treatment and maintain strength.
The timing analysis showed that most of these side effects were reported early in treatment, suggesting doctors should pay special attention during the first weeks and months of therapy. This early monitoring window is critical for catching problems before they become severe.
Beyond the main findings, researchers identified several other concerning patterns. Electrolyte disturbances (imbalances in sodium, potassium, and other minerals) were frequently reported and can cause serious heart and nerve problems if not corrected. Iron overload was another signal, which matters because excess iron can damage organs over time. Failure to thrive in patients (a general decline in health and function) and decreased appetite were also significant, as these can lead to malnutrition and weakness during an already challenging treatment period.
According to Gram Research analysis, this study confirms and expands on what doctors already knew about these medications. Previous studies identified some stomach problems and metabolism issues, but this large real-world analysis shows how common and serious these side effects actually are in everyday practice. The finding that neutropenic colitis is 23-26 times more common than expected is particularly important because it’s a rare condition that doctors might not immediately suspect in cancer patients.
The study has important limitations to understand. It’s based on voluntary reports, meaning some side effects might not be reported while others might be over-reported. The data doesn’t prove the drug caused the problem—only that it was reported more often. Patients taking these drugs often have other serious health conditions that could also cause stomach and nutrition problems. The study couldn’t determine how often these side effects actually occur because not all patients who experience them report them. Finally, the computer analysis exploring how these drugs cause problems is exploratory and needs further research to confirm.
The Bottom Line
If you’re taking azacitidine or decitabine: (1) Tell your doctor immediately about any stomach pain, nausea, vomiting, or diarrhea—don’t wait for your next appointment. (2) Monitor your appetite and try to eat nutritious foods even if you’re not hungry. (3) Have regular blood tests to check electrolytes, protein levels, and iron. (4) Report any unusual weight loss or extreme fatigue. These recommendations are based on strong evidence from thousands of patient reports and should be discussed with your cancer care team.
This research is most important for patients taking azacitidine or decitabine for blood cancers, their families, and their doctors. If you’re starting these medications, ask your doctor about these potential side effects and what warning signs to watch for. If you’re a caregiver, knowing these risks helps you support the patient and recognize problems early. Doctors should use this information to plan monitoring schedules and supportive care strategies.
Most side effects appeared early in treatment (within the first weeks to months), so this is the critical monitoring period. However, some problems like iron overload can develop gradually over longer treatment periods. Improvement typically follows once the side effect is identified and treated, though recovery time varies by individual and the severity of the problem.
Frequently Asked Questions
What stomach problems can happen when taking azacitidine or decitabine?
The most serious is neutropenic colitis (severe colon inflammation), which is 23-26 times more common in patients taking these drugs. Other problems include nausea, vomiting, diarrhea, and loss of appetite. Report any stomach pain or changes immediately to your doctor.
When do side effects from these cancer drugs usually start?
Most gastrointestinal and nutrition-related side effects appear early in treatment, typically within the first weeks to months. This is why close monitoring during the beginning of therapy is especially important for catching problems early.
What nutrition problems can these medications cause?
Common issues include low blood protein levels, electrolyte imbalances (salt and mineral problems), severe weight loss, decreased appetite, and iron buildup. These can weaken patients and slow recovery, making nutritional support an important part of treatment.
How can doctors monitor for these side effects?
Regular blood tests checking electrolytes, protein levels, and iron are essential. Doctors should also ask about stomach symptoms, appetite changes, and weight loss at each visit. Early detection allows for faster treatment of these problems.
Should I avoid these medications because of these side effects?
No. These drugs are effective cancer treatments. Instead, work with your doctor to monitor for side effects closely, especially early in treatment. Knowing what to watch for helps catch problems quickly so they can be treated effectively.
Want to Apply This Research?
- Log daily appetite level (1-10 scale), any stomach symptoms (nausea, pain, diarrhea), and weight weekly. Set reminders for blood test appointments to monitor electrolytes, albumin, and iron levels.
- Create a symptom alert system: if you experience severe stomach pain, vomiting, or sudden appetite loss, immediately notify your care team rather than waiting. Use the app to track which foods you tolerate best and set meal reminders to ensure adequate nutrition despite reduced appetite.
- Establish a weekly check-in routine reviewing appetite trends, stomach symptoms, and weight changes. Flag any new or worsening symptoms for discussion at medical appointments. Track lab results when available to correlate with symptom patterns and identify early warning signs.
This article summarizes research about potential side effects of azacitidine and decitabine. It is not medical advice. If you are taking these medications or considering them, discuss all potential side effects, benefits, and risks with your oncologist or healthcare provider. Do not stop taking prescribed medications without consulting your doctor. This research is based on voluntary safety reports and does not prove these drugs caused specific side effects in individual cases. Always seek immediate medical attention for severe symptoms such as severe abdominal pain, persistent vomiting, or difficulty breathing.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.